Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMOEP in Untreated Peripheral T-cell Lymphoma
NCT05458180Phase 1Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jul 2022
- Primary completion
- Dec 2024
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, open-label trial of mitoxantrone hydrochloride liposome in peripheral T-cell lymphoma (PTCL), sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
mitoxantrone hydrochloride liposome
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT05458180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05458180.